Biodistribution and pharmacokinetics of amblyomin-X, a novel antitumour protein drug in healthy mice

Butantan affiliation
Publication type
Appears in Collections:
Background Amblyomin-X is a recombinant protein under development for cancer treatment owing to its selective cytotoxic activity over several tumour cell lines and tumour regression in mice models. The aim of this study was to examine the distribution and pharmacokinetics of amblyomin-X in healthy female mice. Methods Amblyomin-X was injected intravenously into the healthy animals and at controlled times plasma and organs were removed and analysed for identification and quantification of the protein. Alternatively, the labelled protein was injected into mice and tracked in an in vivo imaging system. Results Amblyomin-X was rapidly eliminated from plasma, probably because of its inability to bind to plasma albumin. After 10 min, the protein was found in the thymus and lungs, and later in the heart, liver and kidneys. In the liver, the protein was found until 24 h after a single injection. The in vivo analysis showed the same kinetics profile, besides the identification of amblyomin-X in the bladder region, indicating its elimination via urine. Only fragments of amblyomin-X were observed in the urine. Conclusions These findings suggest that amblyomin-X is rapidly distributed to the tissues, metabolized by the liver or even kidneys, and eliminated in urine in healthy mice. There is no accumulation in any organ.
Boufleur P, Sciani JM, Goldfeder MB, Faria F, Branco VG, Chudzinski-Tavassi AM. Biodistribution and pharmacokinetics of amblyomin-X, a novel antitumour protein drug in healthy mice. Eur. J. Drug. Metab. Pharmacokinet.. 2019 Feb;44:111-120. doi:10.1007/s13318-018-0500-z.
Link to cite this reference
Issue Date

Show full item record

The access to the publications deposited in this repository respects the licenses from journals and publishers.